fbpx

GBM Awareness Day is July 17. Join us in raising awareness all month long! Learn more.

Pediatric Low-Grade Gliomas (LGG)

Play Video about video overlay

Pediatric Low-Grade Gliomas (LGG)

Pediatric low-grade gliomas (LGG) are a group of slow-growing tumors that can occur in numerous locations throughout the brain and spinal cord. They are the most common central nervous system tumors in children and adolescents. Types of LGG include pilocytic astrocytoma, pilomyxoid astrocytoma, and ganglioglioma. Pediatric LGG rarely spread beyond their site of origin and are often referred to as benign (not cancerous) as most can be cured with surgical removal if this is feasible. However, LGG may occur in sites in the brain such as the vision tracts where surgery is not recommended. In this situation, patients often require multiple courses of therapies, including chemotherapy or radiation, to keep the tumor from growing.

Location

Pediatric LGG occur in any location in the brain or spinal cord but most commonly occur in the bottom portion of the brain known as the cerebellum.

Symptoms

Symptoms depend on the location of the tumor but may include vision changes, headaches, vomiting (most frequently in the morning), or balance issues.

Treatment

If the tumor is in a location where surgery is feasible, the curative treatment for pediatric low-grade gliomas is complete removal. Some LGG do not grow for long periods (or ever), even if a small portion remains after surgery. If a low-grade glioma is detected on imaging but does not grow over time and is not causing symptoms, patients can be observed without treatment as these tumors are not aggressive and typically do not spread.

However, for tumors in areas of the brain where surgery is not feasible (e.g., in the vision tracts where surgery would cause blindness), that grow over time or are causing symptoms, chemotherapy is most common used. There are several chemotherapy drugs and regimens that are used for LGG. These typically consist of low doses of drugs used over a long period of time. The purpose of chemotherapy in low-grade glioma is not to make the tumor disappear, but instead to prevent it from continuing to grow and cause symptoms. Radiation therapy is an extremely effective treatment for LGG, but due to its short- and long-term side effects is typically avoided until patients are at least 10 years old.

More recently, molecularly targeted drugs that work against key cancer pathways and can be taken by mouth have been developed, including drugs that target the MAPK signaling pathway such as Dabrafenib, Trametinib, and Selumetinib. The choice of which type of MAPK pathway inhibitor to take is often based on the specific molecular changes in the patient’s tumor.

Prognosis

Prognosis means a prediction of outcome. This information is usually based on information gathered from groups of people with the same disease. It is important to remember these statistics are not individualized.

The 10-year overall survival for pediatric LGG is over 90%, with the best survival in patients whose tumors can be completely removed with surgery. Tumors that can’t be resected often continue to grow, although this does not typically lead to death.

Incidence

LGG are the most common central nervous system tumors seen in children and adolescents, accounting for about 33% of brain and spinal cord tumors in this population.

Age Distribution

LGG can be diagnosed at any age in pediatric patients from infancy to young adults. LGG diagnosed in infants have a poorer prognosis due to their tendency to spread throughout the central nervous system.

Risk Factors

Patients with Neurofibromatosis Type 1 have a particularly high risk of developing LGG, particularly along their vision tracts; these patients should undergo regular tumor surveillance to detect these tumors early prior to the onset of vision loss. Patients with Tuberous Sclerosis Complex are at higher risk of developing a specific type of LGG known as subependymal giant cell astrocytoma. Patients with Noonan syndrome are also at higher risk of developing LGG in childhood.

Molecular Profile

Molecular profiling is the detection of specific genes, proteins, or other molecules in a tumor. This information helps confirm tumor diagnosis, inform treatment options, and predict prognosis.

All pediatric LGG are characterized by activation of the MAPK pathway. The most common genetic change seen in these tumors is a fusion (abnormal combination) of 2 genes: BRAF and KIAA1549. Other changes may include the BRAFV600E mutation or mutations or fusions of other MAPK pathway genes such as FGFR1/2, NF1, RAF1, or NTRK.

Content last reviewed:

April 2022 by Holly B. Lindsay, MD, MS and Donald Williams (Will) Parsons, MD, PhD

Newly diagnosed?
Start here.

This free “Newly Diagnosed Toolkit” has what you need to get started, including diagnosis, treatment,  tumor-specific information for some tumor types, even a custom notebook and pen to keep track of information from your doctor visits.

Subscribe to MindMatters

Sign up for our bi-monthly email to get the latest news on treatments, support, and stories from the brain tumor community.

Our Support Services are 100% free for patients and caregivers

CareLine

800-886-ABTA (2282) 8:30 AM-5:00 PM CST or info@abta.org
- Information on treatment and care
- Finding brain tumor treatment centers
- Financial assistance resources
- Finding clinical trials

Support Groups

From diagnosis, surgery, and treatment side effects, to recovery and for some—recurrence—you may feel anxious and isolated. Support groups can improve your emotional well-being and quality of life. Virtual and in-person options.

Patient & Caregiver Mentor Support

Our Mentor Program offers patients and caregivers the opportunity to connect with someone who has gone through a similar brain tumor diagnosis, treatment, and care.

Financial Support

Being diagnosed with a brain tumor takes a toll physically, emotionally, and financially. Medical bills and related costs can quickly add up. We have a list of resources to help in addition to the ABTA Financial Assistance Program.

Webinars

The free educational webinar series is an excellent resource for brain tumor patients and caregivers to learn more about brain tumor types, treatments, well-being topics, and research updates from nationally recognized experts.

Educational Resources

- About Brain Tumors
- Questions to Ask Your Doctor
- Tumor-specific educational materials
- Caregiver Handbook
- Clinical Trials
and more

Connections Community

ABTA’s online support community, where brain tumor patients, survivors, and caregivers come together. Information about malignant and non-malignant tumors, GBM, immunotherapy and more.

Patient Family Meetings

Each free, half-day program in this series focuses on a specific topic for brain tumor patients and caregivers, led by nationally recognized experts. Watch one or all. Similar to our Webinars but longer and more in-depth.

Brain Tumor Treatment Center

The ABTA Treatment Center Guide provides detailed information about a variety of treatment centers, including the number of patients treated annually, technologies and specialized procedures offered.

Gina & Tim Abbas
Caregiver & Anaplastic Astrocytoma Survivor

Double Your Impact for Brain Tumor Families

Donate now and your gift will be matched thanks to the Will Hicks Charitable Association.